Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7739526 | 1.00 | CYP2D6 (0.33) | CYP2D6ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL7741087 | 1.00 | CYP2D6 (0.33) | CYP2D6ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL7739844 | 1.00 | CYP2D6 (0.33) | CYP2D6ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL1409045 | 1.00 | CYP2D6 (0.33) | CYP2D6ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL1524683 | 0.97 | — | — | |
| SCHEMBL170561 | 0.91 | — | — | |
| SCHEMBL2460 | 0.84 | — | — | |
| SCHEMBL2878801 | 0.78 | — | — | |
| SCHEMBL10890308 | 0.76 | — | — | |
| SCHEMBL19356840 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| CN-115210219-A | Oxime ester photoinitiators | 巴斯夫欧洲公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220121113-A1 | OXIME ESTER PHOTOINITIATORS HAVING A SPECIAL AROYL CHROMOPHORE | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| CN-113316744-A | Oxime ester photoinitiators with specific aroyl chromophores | 巴斯夫欧洲公司 | 2021-08-27 | — | — | CN | disclosed |
| US-10793555-B2 | Oxime ester photoinitiators | BASF SE (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20180208583-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2018-07-26 | — | — | US | disclosed |
| US-9957258-B2 | Oxime ester photoinitiators | BASF SE (DE) | 2018-05-01 | — | — | US | disclosed |
| US-20160214966-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2016-07-28 | — | — | US | disclosed |
| US-6410748-B1 | Alicycli c group-containing monomer | KABUSHIKI KAISHA TOSHIBA (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6291129-B1 | LIGHT SENSITIVE ELEMENT WITH UNSATURATED POLYMERS | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793555-B2 | Oxime ester photoinitiators | NR2E3, OXER1, CBR3 | CYP2D6 214/4885ALDH1A1 929/4885KDM4E 1413/4885 |
| US-20180208583-A1 | OXIME ESTER PHOTOINITIATORS | NR2E3, OXER1, CBR3 | CYP2D6 214/4885ALDH1A1 929/4885KDM4E 1413/4885 |
| US-20160214966-A1 | OXIME ESTER PHOTOINITIATORS | OCIAD1, OCIAD2, OXER1 | CYP2D6 192/4885ALDH1A1 854/4885KDM4E 966/4885 |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | OCIAD1, OCIAD2, OXER1 | CYP2D6 350/4885ALDH1A1 964/4885KDM4E 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.